FORMULASI NANOPARTIKEL LOSARTAN DENGAN PEMBAWA KITOSAN DAN UJI TRANSPOR TRANSDERMAL SECARA IN VITRO

The nanoparticle in transdermal drug delivery system has been widely developed rapidly to increase skin permeability and to deliver drug into systemic circulation. This research aim was to find out optimal condition of chitosan-losartan nanoparticle and its effect on in vitro transdermal transport....

Full description

Bibliographic Details
Main Authors: , Nuri Ari Efiana, S.F., Apt, , Dr. Akhmad Kharis Nugroho, M.Si., Apt
Format: Thesis
Published: [Yogyakarta] : Universitas Gadjah Mada 2011
Subjects:
ETD
Description
Summary:The nanoparticle in transdermal drug delivery system has been widely developed rapidly to increase skin permeability and to deliver drug into systemic circulation. This research aim was to find out optimal condition of chitosan-losartan nanoparticle and its effect on in vitro transdermal transport. Ionic gelation method was used, and two variables were optimized, i.e. pH (4,0-5,0) and rate of stirring (350-700 rpm). Loading capacity was used as a respon. Experimental transdermal transport was carried out for 28 hours using vertical type diffusion cell. Four formulas, i.e. Formula (F) I (losartan potassium solution in water), F II (nanoparticle dispersion in water), F III (losartan potassium solution in water with 10 % oleic acid in propilenglycol pretreatment), F IV (nanoparticle dispersion in water with 10 % oleic acid in propilenglycol pretreatment) were applied transdermally. The donor compartment contained 2 mL of 2 mg/mL losartan potassium solution. The transport profiles were analyzed using two methods, i.e. lag time diffusion method and compartmental modeling method. The results showed that optimum conditions were gained at pH of 4,0 and stirring rate of 350 rpm and the loading capacity was 47.7%. The mean of nanoparticle size was 290.3 nm and the zeta potential was +50.79 mV. F IV had higher rate of transport and could be applied transdermally in area of 48.58 cm2 to achieve therapeutic plasma level of 10 ng/mL. If the donor concentration of losartan is increased to 10.79 mg/mL the application area is predicted to become 9 cm2.